These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

712 related items for PubMed ID: 25826079

  • 1. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
    Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH.
    Oncotarget; 2015 Apr 20; 6(11):9600-11. PubMed ID: 25826079
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM.
    Ann Surg Oncol; 2012 Sep 20; 19(9):3002-11. PubMed ID: 22437200
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014 Sep 20; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.
    Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.
    Breast Cancer; 2015 Sep 20; 22(5):486-95. PubMed ID: 24338638
    [Abstract] [Full Text] [Related]

  • 5. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN.
    J Clin Oncol; 2017 Apr 01; 35(10):1049-1060. PubMed ID: 28135148
    [Abstract] [Full Text] [Related]

  • 6. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
    Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E.
    Eur J Cancer; 2012 Dec 01; 48(18):3342-54. PubMed ID: 22766518
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
    Dai XL, Han ZB, Yang YT, Qiu J, Liu YF, Feng YZ.
    Int J Clin Pharmacol Ther; 2015 Jul 04; 53(7):517-22. PubMed ID: 25907177
    [Abstract] [Full Text] [Related]

  • 9. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
    Ruano R, Ramos M, García-Talavera JR, Ramos T, Rosero AS, González-Orus JM, Sancho M.
    Rev Esp Med Nucl Imagen Mol; 2014 Jul 04; 33(6):340-5. PubMed ID: 24856234
    [Abstract] [Full Text] [Related]

  • 10. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
    Heikkinen T, Korpela T, Fagerholm R, Khan S, Aittomäki K, Heikkilä P, Blomqvist C, Carpén O, Nevanlinna H.
    Breast Cancer Res Treat; 2013 Aug 04; 141(1):79-88. PubMed ID: 23974830
    [Abstract] [Full Text] [Related]

  • 11. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.
    Jpn J Clin Oncol; 2011 Jul 04; 41(7):867-75. PubMed ID: 21719750
    [Abstract] [Full Text] [Related]

  • 12. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.
    Breast Cancer Res Treat; 2010 Nov 04; 124(2):387-91. PubMed ID: 20824324
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G.
    J Clin Oncol; 2010 Apr 20; 28(12):2024-31. PubMed ID: 20308670
    [Abstract] [Full Text] [Related]

  • 14. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
    von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.
    J Clin Oncol; 2011 Jun 01; 29(16):2150-7. PubMed ID: 21519019
    [Abstract] [Full Text] [Related]

  • 15. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H, Kalogeras KT, Kronenwett R, Alexopoulou Z, Wirtz RM, Zagouri F, Scopa CD, Gogas H, Petraki K, Christodoulou C, Pavlakis K, Koutras AK, Samantas E, Patsea H, Pectasides D, Bafaloukos D, Fountzilas G.
    Anticancer Res; 2015 Jul 01; 35(7):4023-36. PubMed ID: 26124351
    [Abstract] [Full Text] [Related]

  • 16. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Campbell EJ, Tesson M, Doogan F, Mohammed ZMA, Mallon E, Edwards J.
    Br J Cancer; 2016 Oct 11; 115(8):967-973. PubMed ID: 27657341
    [Abstract] [Full Text] [Related]

  • 17. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S, Huang L, Chen CM, Shao ZM.
    Oncotarget; 2015 Jul 20; 6(20):18174-82. PubMed ID: 26053183
    [Abstract] [Full Text] [Related]

  • 18. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
    Lv M, Li B, Li Y, Mao X, Yao F, Jin F.
    Asian Pac J Cancer Prev; 2011 Jul 20; 12(9):2411-7. PubMed ID: 22296393
    [Abstract] [Full Text] [Related]

  • 19. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Iwase M, Ando M, Aogi K, Aruga T, Inoue K, Shimomura A, Tokunaga E, Masuda N, Yamauchi H, Yamashita T, Iwata H.
    Breast Cancer Res Treat; 2020 Apr 20; 180(3):687-694. PubMed ID: 32140811
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM, Lowe KA, Atwood M, Beatty JD.
    Breast J; 2010 Apr 20; 16(4):362-8. PubMed ID: 20443786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.